Hemosol B0

Hemosol B0 is an intravenous solution containing calcium, lactic acid, magnesium, sodium, chloride ion, and hydrogen carbonate. It is formulated for use in haemodialysis and other intravenous applications, providing electrolyte and acid‑base balance support. The product is marketed in the European Union and supplied without a specific brand name, adhering to standard pharmaceutical quality specifications. The solution is sterile, isotonic, and intended for administration under medical supervision.

Hemosol B0 is primarily employed in clinical settings where precise electrolyte and acid‑base management is required.

- Maintenance of electrolyte concentrations during haemodialysis. - Correction of mild metabolic acidosis in patients receiving renal replacement therapy. - Support of calcium and magnesium balance in critically ill patients. - Provision of sodium and chloride to stabilize plasma osmolality. - Use as a compatible carrier solution for intravenous drug admixtures.

Adverse reactions to Hemosol B0 are generally infrequent, but they can be categorized by frequency and severity.

Common: - Mild infusion site irritation or erythema. - Transient nausea or vomiting. - Slight increase in serum calcium or magnesium levels. - Temporary headache or dizziness.

Serious: - Severe hypercalcemia or hypermagnesemia. - Rapid shifts in blood pH leading to metabolic alkalosis. - Anaphylactic or severe hypersensitivity reactions. - Pulmonary edema from fluid overload.

When using Hemosol B0, clinicians should observe several precautionary measures to minimize risk.

- Verify patient electrolyte and acid‑base status before initiation. - Adjust infusion rate in patients with cardiac or renal impairment. - Monitor serum calcium, magnesium, and bicarbonate levels during therapy. - Avoid use in patients with known hypersensitivity to any component. - Use caution in pregnant or lactating individuals until safety is established. - Ensure compatibility with other intravenous solutions to prevent precipitation.

Hemosol B0 may interact with other medications or solutions; awareness of these interactions helps maintain safety.

Avoid: - Concurrent administration with calcium channel blockers that may exacerbate hypercalcemia. - Co‑infusion with high‑dose bicarbonate solutions, which can cause excessive alkalosis. - Use with blood products containing citrate, increasing risk of electrolyte imbalance.

Use with caution: - Loop diuretics, which can alter calcium and magnesium excretion. - ACE inhibitors or ARBs, where shifts in sodium and potassium may affect blood pressure control. - Anticoagulants used during haemodialysis, requiring monitoring of clotting parameters.